Across six studies covering 2,487 patients with obesity, type 2 diabetes and chronic kidney disease, metabolic surgery outperformed GLP-1 agonists on renal endpoints. CKD progression fell to 21.7% versus 45.1%, renal failure to 24.0% versus 43.8%, and CKD remission reached 82.4% versus 55.1%. Surgery also lifted transplant eligibility to 19.7% versus 2.1%. Two Markov models projected 5-year transplant rates of 14.7% after sleeve gastrectomy versus 4.8% with GLP-1 therapy.
The direction fits what we know: surgery produces larger, more durable weight loss than semaglutide or tirzepatide, and weight loss is a main driver of kidney benefit, alongside improved glycemia and blood pressure. But the evidence base is thin and weak. Only one randomized trial was included, three studies were retrospective, and two were simulations rather than observed outcomes. Surgical patients are typically selected for fitness and motivation, so confounding by indication likely inflates the gap. The pooled percentages come from different studies with different populations and follow-up, and the authors used simple descriptive statistics rather than a formal meta-analysis. Newer, more potent incretin drugs and the dedicated kidney-outcome data for semaglutide (FLOW trial) may be underrepresented. Treat this as hypothesis-generating: it supports discussing surgical referral with a nephrologist and bariatric team for eligible patients, but it does not show surgery is superior, and head-to-head randomized trials are still needed.